Clinical trials in Maastricht – page 69

1 387 clinical trials in Maastricht, The Netherlands across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Maastricht at a glance

1 387

clinical trials

Research sites6

Quick filters

1 387 trials in Maastricht

Open in trial search

Triple negative breast cancer

Not recruiting

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Interferon BETA-1A
Sponsor:Synairgen Research Limited

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pelacarsen
Sponsor:Novartis Pharma AG

Contact Research Centre

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Hypersomnia

Not recruiting

Study of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia

Investigational

Study of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:ALKS 2680
Sponsor:Alkermes Inc.

Contact Research Centre

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Congenital cystic kidney disease

Not recruiting

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational

The Netherlands

Participants:18–64 years
Substances:ABBV-CLS-628
Sponsor:Calico Life Sciences LLC

Contact Research Centre

Breast cancer+2

Not recruiting

Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

Registered drugNo placebo

Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Trastuzumab
Sponsor:Institut Jules Bordet

Contact Research Centre

Sickle cell disease

Not recruiting

Study on the Effects of Tebapivat and AG-946 in Patients with Sickle Cell Disease

Investigational

Study on the Effects of Tebapivat and AG-946 in Patients with Sickle Cell Disease

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Agios Pharmaceuticals Inc.

Contact Research Centre

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Argenx

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rocatinlimab
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Maastricht

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer, and melanoma treatments. Studies include novel therapy combinations and personalized treatment approaches.

Advanced treatment protocols for metastatic conditions
Immunotherapy interventions
Diagnostic imaging improvements

Particular emphasis on targeted therapies and treatment optimization for various cancer types.

02 Chronic Disease Management

Research focusing on chronic kidney disease, fibromyalgia, and inflammatory bowel conditions. Studies evaluate new therapeutic approaches and treatment combinations.

Novel drug combinations
Disease progression monitoring
Quality of life improvements

Emphasis on developing effective long-term management strategies for chronic conditions.

03 Cardiovascular Studies

Investigations into peripheral arterial disease and cardiomyopathy treatments. Research includes innovative therapeutic approaches and preventive strategies.

Cardiovascular risk reduction
Treatment optimization
Disease prevention protocols

Focus on improving patient outcomes through targeted interventions and preventive measures.

Back to the Netherlands All countries